department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Reblozyl · pharmadog

pharmadog
drugs
Reblozyl

drug

patient view →

luspatercept

Marketedupdated 2mo ago

by Celgene Corp

Approved

community read0 votes

all catalysts(6)

approval · 6

REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval

REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval

REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval

REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval

REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval

REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Reblozyl

generic

luspatercept-aamt

indication

Anemia

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval24 co-mentions · 6 sources
drugREBLOZYL24 co-mentions · 6 sources
companyCelgene Corp12 co-mentions · 6 sources

Trials studying luspatercept

—A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemiaterminatedn=30
—Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in Chinacompletedn=88
phase2Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosisrecruitingn=68
phase3ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusionsrecruitingn=360
phase2Luspatercept for Clonal Cytopenias of Uncertain Significancerecruitingn=50
phase2A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemiarecruitingn=189
phase2Luspatercept + Darbepoetin in MDSrecruitingn=60
—A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spainactive not recruitingn=1,300

more trials →